Gemcitabine and taxanes in metastatic breast cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Amadori, D ^a   Cecconetto, L ^b  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Gemcitabine; Metastatic breast cancer; Taxanes; Translational research

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LIVER DYSFUNCTION; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; TAXOIDS;

EID: 33745590718     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj976     Document Type: Article

References (30)

1. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: Metabolism, mechanism of action, and self self-potentetion. Sem Oncol 1995; 22 (Suppl 11): S3-10.
2. Huang P, Chubb S, Hertel LW et al. Mechanism of action of 2′,2′-difluorodeoxycytidine triphosphate on DNA synthesis. Proc Am Ass Cancer Res 1990; 31: (Abstr 426).
3. Blackstein M, Vogel CL, Ambinder R et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 2002; 62: 2-8.
4. Possinger K, Kaufmann M, Coleman R et al. Phase II study of gemcitabine as first line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999; 10: 155-162.
5. Spielmann M, Llombart-Cussac A, Kalla S et al. Single agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303-307.
6. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-2736.
7. Brodowicz T, Kostler WJ, Moslinger R et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000; 9: 338-342.
8. Smorenburg CH, Bontenbal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001; 66: 83-87.
9. Theodossiou C, Cook JA, Fisher J et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998; 12: 825-832.
10. Kroep JR, Giaccone G, Tolis C et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer; 83: 1069-1076.
11. Zoli W, Ricotti L, Barzanti F et al. Schedule dependent interaction of doxorubicin, paclitaxel and.gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80: 413-416.
12. Colomer R, Llombart A, Lluch A et al. Biweekly paclitaxel and gemcitabine in advanced breast cancer. Phase II trial and predictve value of HER 2 extracellular domain. Proc Am Soc Clin Oncol 2000; 19: (Abstr 373).
13. Delfino C, Caccia GM, Riva Gonzalez L et al. Gemcitabine plus paclitaxel administered as first-line chemotherapy for patients with advanced breast cancer. Proc Am Soc Clin Oncol 2002; (Abstr 2025).
14. Genot JY, Tublana-Hulin M, Tubiana-Mathieu N et al. Gemcitabine and paclitaxel in metastatic breast cancer: A phase II study in the first line setting. Proc Am Soc Clin Oncol 2002; (Abstr 2002).
15. Murad AM, Guimaraes RC, Aragao BC et al. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol 2001; 24: 264-268.
16. Sanchez-Rovira P, Gonzalez E, Medina MB et al. Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Breast Cancer Res Treat 1999, 57: 87.
17. Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc Am Soc Clin Oncol 2004; (Abstr 510).
18. Moinpour C, Wu J, Donaldson G et al. Gemcitabine plus paclitaxel versus paclitaxel as first line treatment for anthracycline pre-treated metastatic breast cancer: Quality of life and pain palliation results from global phase III trial. Proc Am Soc Clin Oncol 2004; (Abstr 621).
19. Conte PF, Gennari A, Donati S et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: A phase II study. Breast Cancer Res Treat 2001; 68: 171-179.
20. Zielinski C, Semir B, Zrinka MK et al. Gemcitabine, epirubicin, and pacitaxel versus fluorouracil, epirubicin and cyclophosphamide as first line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005; 23: 1401-1408.
21. Ricotti L, Tesei A, De Paola F et al. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 2003; 9: 900-905.
22. Denes AE, Needles BM, Schmidt A. A comparison of two schedules of docetaxel in combination with gemcitabine given every other week. Proc Am Soc Clin Oncol 2000; (Abstr 828).
23. Alexopulos A, Tryfonopoulos D, Karamouzis MV et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 2004; 15: 95-99.
24. Kornek GV, Haider K, Kwasny W et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 2002; 8: 1051-1056.
25. Palmeri S, Vagliaca M, Accurso V et al. Weekly docetaxel (Doc) + gemcitabine (Gem) as first line for advanced breast cancer (ABC): A multicenter phase II study. Proc Am Soc Clin Oncol 2002; (Abstr 1991).
26. Garle PA, Calvo LS, Mayordomo A et al. Gemcitabine and Docetaxel given every other week as first line therapy for metastatic breast cancer (MBC): Final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group. Proc Am Soc Clin Oncol 2003; (Abstr 201).
27. Fountzilas G, Nicolaides C, Bafaloukos D et al. Docetaxel and gemcitabine in anrthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000; 18: 503-509.
28. Mavroudis D, Malamos N, Alexopulos A et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Ann Oncol 1999; 10: 211-215.
29. Brandi M, Vici P, Lopez M et al. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: Result of a multicenter phase II study. Semin Oncol 2004; 31 (Suppl 5): 13-19.
30. Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. Proc Am Soc Clin Oncol Proc 2005; (Abstr 581).